TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01607554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician
Study: NCT02372656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Metformin
Description: 1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.2% Simvastatin
Description: 1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
Study: NCT04278157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
Description: The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
Study: NCT02521311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine
Description: 12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
Study: NCT01925287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
Study: NCT04723420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Steamroller technique
Description: Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct technique
Description: Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
Study: NCT00319839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 260 mg/m2 IV over 30 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
Study: NCT04647643

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel to treat peripheral arterial disease

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel to treat peripheral arterial disease
Study: NCT05784220

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DPP Curriculum for Lifestyle Intervention
Description: See arms.
Study: NCT02682524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac 100mg tab.
Study: NCT01577745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
Study: NCT03375216

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
Study: NCT01990209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Study: NCT03910244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide Oral Product
Description: Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
Study: NCT01131234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04537182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Description: Lung volume reduction by surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic lung volume reduction with valves
Description: Lung volume reduction with endobronchial valves.
Study: NCT03910244

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo will be given.
Study: NCT00821795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH/Regular 70/30 mix
Description: injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart protamine/insulin aspart 70/30 mix
Description: injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
Study: NCT02636595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT01952223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy
Description: Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy
Description: Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prostate radiotherapy
Description: Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: prostate radiotherapy
Description: Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy
Study: NCT03561012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-Based Goals and Incentives
Description: The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Standard of care
Study: NCT02963103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study: NCT01147237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracoronary stent implantation
Description: Everolimus-eluting stent implantation in patients with long coronary artery disease
Study: NCT01778023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
Study: NCT03875846

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative Hemodynamic Pressures
Description: Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Flow Rate
Description: A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
Study: NCT02934425

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined carbohydrate-rich breakfast
Description: Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
Study: NCT02773836

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
Study: NCT00509964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILF
Description: Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
Study: NCT00099736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Description: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Description: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Study: NCT02934425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High pork protein breakfast
Description: High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
Study: NCT04580966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR) workshop
Description: The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
Study: NCT02113930

Intervention type: BIOLOGICAL
Intervention: Constitution of a biobank of frozen cells, plasma and serum samples
Description: Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).

Intervention type: GENETIC
Intervention: Genetic study
Description: High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
Study: NCT04076839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
Study: NCT03488433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abduction brace
Description: Donjoy Ultrasling IV
Study: NCT03713736

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cervical smear
Description: Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
Study: NCT03488433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antirotation sling
Description: Donjoy shoulder immobilizer
Study: NCT01122862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% chlorhexidine mouthrinse
Description: commercially available 0.12% chlorhexidine mouthrinse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cosmetic mouthrinse
Description: Commerically available cosmetic mouthrinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water
Study: NCT03434678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml
Description: Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol+ Rocuronium+ Fentanyl + Inhalational
Description: Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Pancreaticoduodenectomy
Description: Whipple' Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Pancreaticoduodenectomy
Description: Whipple' Procedure
Study: NCT01175447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
Study: NCT03866304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: S2 Picosecond laser
Description: Each subject will receive up to 16 laser treatments.
Study: NCT03482154

Intervention type: PROCEDURE
Intervention: Hematopoietic Stem Cell Transplant
Description: Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.

Intervention type: PROCEDURE
Intervention: Hematopoietic Stem Cell Transplant
Description: Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
Study: NCT02752074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab + epacadostat
Description: * Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Epacadostat will be administered orally daily starting at Day 1 (Week 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab + placebo
Description: * Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Placebo will be administered orally daily starting at Day 1 (Week 1)